{"id":"savolitinib-osimertinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Savolitinib is a MET inhibitor that addresses MET-driven resistance to EGFR inhibitors, while osimertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR mutations. The combination is designed to prevent or overcome acquired resistance in EGFR-mutant non-small cell lung cancer by simultaneously blocking both EGFR and MET signaling pathways.","oneSentence":"Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:38.532Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"EGFR-mutant non-small cell lung cancer (NSCLC) with MET alterations or at risk of MET-driven resistance"}]},"trialDetails":[{"nctId":"NCT04606771","phase":"PHASE2","title":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-09-28","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03778229","phase":"PHASE2","title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-09","conditions":"Carcinoma","enrollment":367},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT07322783","phase":"PHASE2","title":"Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2025-01-01","conditions":"EGFR Positive Non-small Cell Lung Cancer, MET Amplification","enrollment":60},{"nctId":"NCT05009836","phase":"PHASE3","title":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchison Medipharma Limited","startDate":"2021-09-06","conditions":"Non-small Cell Lung Cancer","enrollment":320},{"nctId":"NCT05015608","phase":"PHASE3","title":"Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchison Medipharma Limited","startDate":"2021-11-22","conditions":"Non-small Cell Lung Cancer","enrollment":250},{"nctId":"NCT03944772","phase":"PHASE2","title":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-06-25","conditions":"Non-Small Cell Lung Cancer","enrollment":247},{"nctId":"NCT05261399","phase":"PHASE3","title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-08-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":324},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT05163249","phase":"PHASE2","title":"Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2022-05-31","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Savolitinib + Osimertinib","genericName":"Savolitinib + Osimertinib","companyName":"Hutchison Medipharma Limited","companyId":"hutchison-medipharma-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer. Used for EGFR-mutant non-small cell lung cancer (NSCLC) with MET alterations or at risk of MET-driven resistance.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}